News | August 13, 2021
Aurobindo Pharma buys Cronus Pharma Specialities for Rs 420 crores
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Income declines marginally
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company has strong product launches both in India and overseas
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
Subscribe To Our Newsletter & Stay Updated
